Do we follow the guidelines: first systemic therapy choice for metastatic hormone receptor-positive breast cancer patients treated at the Institute for Oncology and Radiology in Serbia

Serovic K.; Jokic V.; Bozovic-Spasojevic I.

首页> 外文期刊>The Breast : >Do we follow the guidelines: first systemic therapy choice for metastatic hormone receptor-positive breast cancer patients treated at the Institute for Oncology and Radiology in Serbia

【24h】

Do we follow the guidelines: first systemic therapy choice for metastatic hormone receptor-positive breast cancer patients treated at the Institute for Oncology and Radiology in Serbia

机译：我们遵循指南：第一个全身治疗选择在塞尔维亚治疗肿瘤学和放射学院治疗的转移激素受体阳性乳腺癌患者

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《The Breast :》 |2019年第1期|共2页
作者
Serovic K.; Jokic V.; Bozovic-Spasojevic I.;
展开▼
作者单位

Inst Oncol &

Radiol Serbia Med Oncol Belgrade Serbia;

Inst Oncol &

Radiol Serbia Med Oncol Belgrade Serbia;

Inst Oncol &

Radiol Serbia Med Oncol Belgrade Serbia;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类胸部外科学;
关键词

相似文献

外文文献
中文文献
专利

1. Do we follow the guidelines: first systemic therapy choice for metastatic hormone receptor-positive breast cancer patients treated at the Institute for Oncology and Radiology in Serbia [J] . Serovic K., Jokic V., Bozovic-Spasojevic I. The Breast : . 2019,第期

机译：我们遵循指南：第一个全身治疗选择在塞尔维亚治疗肿瘤学和放射学院治疗的转移激素受体阳性乳腺癌患者
2. Hormonal therapy might be a better choice as maintenance treatment than capecitabine after response to first-line capecitabine-based combination chemotherapy for patients with hormone receptor-positive and HER2-negative, metastatic breast cancer [J] . Xue-Lian Chen, Feng Du, Ruo-Xi Hong, Chinese journal of cancer . 2016,第1期

机译：对于激素受体阳性和HER2阴性，转移性乳腺癌的患者，在一线基于卡培他滨的联合化疗后，激素治疗可能是比卡培他滨更好的维持治疗方法
3. Hormonal therapy might be a better choice as maintenance treatment than capecitabine after response to first-line capecitabine-based combination chemotherapy for patients with hormone receptor-positive and HER2-negative, metastatic breast cancer [J] . Xue-Lian Chen, Feng Du, Ruo-Xi Hong, Cancer Communications . 2016,第1期

机译：对于激素受体阳性和HER2阴性，转移性乳腺癌的患者，在一线基于卡培他滨的联合化疗后，激素治疗可能是比卡培他滨更好的维持治疗方法
4. When to Treat Metastatic Renal Cell Carcinoma Comorbidities, Systemic Therapy, and Active Surveillance in Metastatic Kidney Cancer [C] . Brian I. Rini Genitourinary Cancers Symposium . 2012

机译：何时治疗转移性肾细胞癌的组合，全身治疗，以及在转移性肾癌中的活跃监测
5. Treatment Interruption and Discontinuation of Hormone Therapy in Hormone Receptor-Positive Breast Cancer Patients [D] . Mao, Daqin . 2020

机译：激素受体阳性乳腺癌患者中的治疗中断与激素治疗中的中断和停止
6. Hormonal therapy might be a better choice as maintenance treatment than capecitabine after response to first-line capecitabine-based combination chemotherapy for patients with hormone receptor-positive and HER2-negative metastatic breast cancer [O] . Xue-Lian Chen, Feng Du, Ruo-Xi Hong, 2016

机译：对于激素受体阳性和HER2阴性转移性乳腺癌的患者在一线基于卡培他滨的联合化疗后激素治疗可能是比卡培他滨更好的维持治疗方法
7. Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology Guideline [O] . Rugo Hope S, Rumble R Bryan, Macrae Erin, 2016

机译：激素受体阳性转移性乳腺癌的内分泌治疗：美国临床肿瘤学会指南

Do we follow the guidelines: first systemic therapy choice for metastatic hormone receptor-positive breast cancer patients treated at the Institute for Oncology and Radiology in Serbia

著录项

相似文献

相关主题

期刊订阅